Transplantation-related events
. | ATG dose* . | . | . | |
|---|---|---|---|---|
. | High n = 46 . | Low n = 55 . | P . | |
| Acute GVHD | ||||
| No. evaluable | 45 | 55 | ||
| Grade (%) | ||||
| 0 | 27 (60) | 15 (27) | .001 | |
| I | 7 (16) | 15 (27) | ||
| II | 5 (11) | 14 (26) | ||
| III-IV | 6 (13) | 11 (20) | ||
| Median time to onset of acute GVHD, d (range) | 33 (13-62) | 30 (8-74) | NS | |
| Chronic GVHD (%) | ||||
| No. evaluable | 31 (67) | 37 (67) | ||
| Extensive chronic GVHD | 10 (32) | 16 (43) | .02 | |
| Limited chronic GVHD | 5 (16) | 12 (32) | ||
| Median time to onset of chronic GVHD, d (range) | 132 (100-450) | 100 (100-253) | .008 | |
| Mode of onset of chronic GVHD (%) | ||||
| Progressive | 3 (20) | 13 (46) | ||
| Quiescent | 5 (33) | 10 (36) | .09 | |
| De novo | 7 (47) | 5 (18) | ||
. | ATG dose* . | . | . | |
|---|---|---|---|---|
. | High n = 46 . | Low n = 55 . | P . | |
| Acute GVHD | ||||
| No. evaluable | 45 | 55 | ||
| Grade (%) | ||||
| 0 | 27 (60) | 15 (27) | .001 | |
| I | 7 (16) | 15 (27) | ||
| II | 5 (11) | 14 (26) | ||
| III-IV | 6 (13) | 11 (20) | ||
| Median time to onset of acute GVHD, d (range) | 33 (13-62) | 30 (8-74) | NS | |
| Chronic GVHD (%) | ||||
| No. evaluable | 31 (67) | 37 (67) | ||
| Extensive chronic GVHD | 10 (32) | 16 (43) | .02 | |
| Limited chronic GVHD | 5 (16) | 12 (32) | ||
| Median time to onset of chronic GVHD, d (range) | 132 (100-450) | 100 (100-253) | .008 | |
| Mode of onset of chronic GVHD (%) | ||||
| Progressive | 3 (20) | 13 (46) | ||
| Quiescent | 5 (33) | 10 (36) | .09 | |
| De novo | 7 (47) | 5 (18) | ||
Because of rounding, not all percentages total 100.
NS indicates not significant.
High ATG dose was 10 or 7.5 mg/kg, and low ATG dose was 2.5 mg/kg.